focus -WSS

focus

author：hotspot 2025-09-28 21:06:42 - browse：5

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Readout Newsletter: Illumina, CRISPR, Regeneron

WSS

Steward Health Care expansion into Malta flopped

Texas Department of Public Safety speaks out on migrant abuse allegations

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Yancopoulos of Regeneron works to expand Dupixent success

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

entertainment

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Psychedelics group wrestles with new pharma identity

Biotech investment managers search for lucrative opportunities

Guidelines to prevent youth baseball injuries need more muscle

Chinese researcher claims birth of first gene

Bright Health sells Medicare Advantage business to Molina

Mirador, a new biotech startup, launches with $400 million

How to save PrEP access — and even expand it

Ending racial health disparities hinges on penalties, political will

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Surgeons perform first xenotransplant using CRISPR'd pig kidney

explore

This gene therapy has record $4.25 million price. It's saved children.

Winning ticket for $1 billion Powerball jackpot sold in California

Stanford president faces new allegations over 1999 paper

U.K. officials, researchers try to ease path for bespoke genetic treatments

Mirador, a new biotech startup, launches with $400 million

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

explore

knowledge

hotspot

knowledge